找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Development of Antibody-Based Therapeutics; Translational Consid Mohammad A. Tabrizi,Gadi G. Bornstein,Scott L. Kla Book 20121st edition Sp

[复制链接]
楼主: mobility
发表于 2025-3-26 22:14:47 | 显示全部楼层
Biophysical Considerations for Development of Antibody-Based Therapeutics,–antigen complexes for drug candidate optimization and the design of clinical dosing strategies. For measuring the dissociation equilibrium constants of mAbs binding reversibly to antigens, two premier technologies are commonly used: Biacore surface plasmon resonance (SPR) and the solution-based kin
发表于 2025-3-27 02:07:59 | 显示全部楼层
发表于 2025-3-27 05:46:01 | 显示全部楼层
Bioanalytical Considerations for Development of Antibody-Based Therapeutics: Pharmacokinetics and Ifor successful translation of information into the later phases of antibody development require the use of relevant bioanalytical (BA) methodologies from early preclinical stages. Here, we discuss a suite of BA methodologies that can be used to enable pharmacokinetics, immunogenicity, and biomarker
发表于 2025-3-27 10:56:23 | 显示全部楼层
发表于 2025-3-27 16:09:16 | 显示全部楼层
发表于 2025-3-27 19:24:59 | 显示全部楼层
发表于 2025-3-28 00:17:34 | 显示全部楼层
Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Theraplved from a simple descriptive endeavor to an essential component of model-based drug development. The role of PK/PD modeling can be more critical for antibody-based therapeutics owing to their complex pharmacological properties. Nonlinear behavior can manifest in most of the physiological processes
发表于 2025-3-28 03:26:02 | 显示全部楼层
Application of Population Pharmacokinetic-Pharmacodynamic Approaches in the Design of Translational few decades. The development of antibody-based therapeutics has benefited substantially from the utilization of population approaches. Moreover, almost all FDA-approved monoclonal antibody therapeutics have been evaluated using population approaches. In this chapter, application of population PK-PD
发表于 2025-3-28 08:38:47 | 显示全部楼层
Translational Biomarkers: Essential Tools in Development of Antibody-Based Therapeutics,f relevant biomarkers can streamline this process significantly. Selecting and evaluating relevant biomarkers early on not only lessens the time and cost associated with clinical evaluation, but also fosters implementation of rational decision-making processes throughout various antibody development
发表于 2025-3-28 11:51:10 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-23 14:07
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表